Tourmaline Bio to Present at the Jefferies Global Healthcare Conference
2024年5月23日 - 8:10PM
Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage
clinical biotechnology company developing transformative medicines
to dramatically improve the lives of patients with life-altering
immune and inflammatory diseases, today announced that Sandeep
Kulkarni, CEO, is expected to participate in the following investor
conference:
Jefferies Global Healthcare
Conference, New YorkCorporate PresentationThursday,
June 6, 2024 at 2:30 pm ET
A live webcast and replay will be posted under
"Events and Presentations" in the News & Investors section of
the Tourmaline Bio website
at https://ir.tourmalinebio.com.
About Tourmaline Bio,
Inc. Tourmaline is a late-stage clinical
biotechnology company driven by its mission to develop
transformative medicines that dramatically improve the lives of
patients with life-altering immune and inflammatory diseases.
Tourmaline’s lead asset is TOUR006.
About TOUR006TOUR006 is a
long-acting, fully human, anti-IL-6 monoclonal antibody with
best-in-class potential and differentiated properties, including a
naturally long half-life, low immunogenicity, and high binding
affinity to IL-6. TOUR006 has been previously studied in 448
participants, including patients with autoimmune disorders, across
six completed clinical trials. Tourmaline is developing TOUR006 in
TED and ASCVD as its first two indications, with additional
diseases under consideration.
Contact:
Meru AdvisorsLee M.
Sternlstern@meruadvisors.com
Tourmaline Bio (NASDAQ:TRML)
過去 株価チャート
から 5 2024 まで 6 2024
Tourmaline Bio (NASDAQ:TRML)
過去 株価チャート
から 6 2023 まで 6 2024